At Ferrer, we focus on identifying projects with differential value
Digital health and technology
This department leads innovation in digital health, the meeting point of technology, health, healthcare and society. Through the "Ferrer 4 Future" programme, we put challenges to the entrepreneurial ecosystem and collaborate with technology-based companies to solve them. In 2020, we focused on solutions for neurological disorders that present with movement abnormalities.
This is a Ferrer company established in Mountain View, California (United States), which owns the proprietary Staccato® platform for pulmonary administration of active ingredients, which achieves, through a non-invasive route, identical pharmacokinetics to intravenous administration by a non-invasive route. Alexza projects induce a clinical response within minutes of inhaled drug administration. They are aimed at the acute symptomatic treatment of central nervous system diseases. Alexza has various products in active development in fields such as Parkinson's disease and gastroenterology.
How the Staccato® system works
The Staccato device contains a rapid heating system capable of reaching very high temperatures in as little as 100 milliseconds, so that the unformulated active ingredient, deposited in a thin layer on a stainless steel substrate, is vaporised. When the patient inhales through the Staccato system, the surface of the stainless steel substrate is instantly heated, creating aerosolised drug particles.
The patient inhales these particles, and their size allows them to reach the deepest and most vascularised areas of the lung. This achieves rapid and complete absorption into the bloodstream.